ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1686716
This article is part of the Research TopicAdvances in Genomic Medicine and Gynecological SciencesView all 5 articles
Predictive Prognostic Value and Early Response Stratification of a Multi-Biomarker Panel for Therapeutic Efficacy and Prognosis in Cervical Cancer Patients Undergoing Chemoradiotherapy
Provisionally accepted- Pingxiang Maternal and Child Health Hospital, Jiangxi, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Aims: Despite progress in chemoradiotherapy (CRT), outcomes in cervical cancer still vary widely. Minimally invasive biomarkers may enable risk stratification and treatment optimization. Methods: We prospectively enrolled 164 International Federation of Gynecology and Obstetrics (FIGO) IB–IVA patients, all receiving CRT plus brachytherapy. Baseline blood markers and HPV subtypes were assessed. Treatment response was evaluated at three months, and progression-free (PFS) and overall survival (OS) were measured over a median of 36 months. Results: Elevated squamous cell carcinoma antigen (SCC-Ag), Cancer antigen 125 (CA125), Interleukin-6 (IL-6), C-reactive protein (CRP), and high neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (NLR/PLR) correlated with advanced disease. At three months, 87.1% showed complete response (CR) or partial response (PR). Higher IL-6, CRP, SCC-Ag, CA125, and NLR/PLR were linked to poorer response. At 36 months, PFS and OS were 65.2% and 74.5%, respectively. High-risk patients had lower PFS (58.1% vs. 72.4%) and OS (64.5% vs. 82.0%), independent of stage, with no increase in severe toxicity. Conclusions: A multi-biomarker panel better predicts treatment response and survival in locally advanced cervical cancer shows superior discrimination for early response and is prognostic for survival in locally advanced cervical cancer. Larger, multi-institutional studies are warranted to validate this panel, standardize assays, and investigate additional markers or imaging-based strategies, ultimately facilitating more personalized therapy and improved outcomes. shows superior discrimination for early response and is prognostic for survival in locally advanced cervical cancer.
Keywords: cervical cancer, Chemoradiotherapy, multi-biomarker panel, treatment response, prognosis, Human papillomavirus, Inflammation, risk stratification
Received: 15 Aug 2025; Accepted: 06 Oct 2025.
Copyright: © 2025 Wang, Gan, Ning and Qiu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yu Wang, wangyu0000003@126.com
Yinting Qiu, 282244709@qq.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.